Stocks股票 / Health Care / VCEL
Vericel · Health Care
VCEL US listed · USD美股 · 美元
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.Vericel Corporation 是一家公开交易的美国生物制药公司，2014年10月前名为Aastrom Bio。Aastrom Bio于1989年在密歇根州安娜堡成立。
Mid cap中盘 · $2B
Rate-sensitive利率敏感
Health Care
S&P 600标普600小盘Russell 2000罗素2000
$45.88
-$0.76 · -1.63%
52w low52周低 $28.56high高 $49.18
Extended — don't chase; wait for a pullback过度拉升 — 勿追高；等待回撤
The bottoming setup is not yet confirmed (price still below the 10-day average) and oscillators are already extended/overbought — not a safe entry. Wait for…筑底形态尚未确认（价格仍位于 10 日均线下方），且摆动指标已过热——此处入场风险较高。等待价格收复 10 日均线且动量趋于稳定后再考虑建仓。
Engine read引擎解读 · 2026-07-21
Price chart价格图表
daily · interactive日线 · 可交互
Open in Terminal打开终端 ↗
Loading chart…图表加载中…
The interactive chart could not load here.互动图表暂时无法在此加载。
Open the live chart in Terminal在终端中打开实时图表 ↗
Candles, volume and moving averages — pan and zoom inside the chart.蜡烛图、成交量与均线 — 图内可缩放拖动。
MMastermind Terminal — live & interactiveMastermind 终端 — 实时互动 ↗
Technicals技术面
daily bars日线数据 · 2026-07-21
Momentum (RSI 14)动量（RSI 14）
58
Neutral zone中性区域
vs 50-day average相对50日均线
+16.4% above上方
Uptrend intact趋势完好
vs 200-day average相对200日均线
+24.7% above上方
Long trend up长期向上
Volatility波动率
35th percentile第35百分位
These readings feed the stance at the top — one source per number, refreshed nightly.以上读数构成页首的引擎立场 — 每个数字只有一个来源，每晚更新。
Earnings财务业绩
next report下次财报 2026-07-3010days to go天后公布
Estimates being raised — 1 analysts预期上调 — 1 位分析师
Valuation估值
Expensive vs sector相对行业偏贵| Multiple指标 | VCEL | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（历史） | 140.60x | 28.59 | |
| P/B市净率 | 6.55x | 3.44 | |
| P/S市销率 | 8.41x | 2.97 | |
| Earnings yield盈利收益率 | 0.71% | 2.72 | |
| FCF yield自由现金流收益率 | 1.07% | 4.00 | |
| EV/EBITDA企业价值/EBITDA | 98.39x | 18.18 | |
| P/FCF市值/自由现金流 | 93.84x | 22.08 |
"Cheaper than" = share of sector peers trading richer on that multiple.「相对便宜」= 行业中该指标估值更高的同行占比。
Financials财务数据
fiscal years财年Revenue营业收入
5-yr growth5年复合增速 17.3%
Earnings per share每股收益
5-yr growth5年复合增速 39.8%
Free cash flow自由现金流
Gross margin毛利率
74.4%
Operating margin营业利润率
4.0%
Net margin净利率
6.0%
FCF margin自由现金流利润率
18.8%
Balance-sheet quality财务体质 7/8
Bankruptcy risk: safe zone破产风险：安全区
Return on equity股本回报率 5%
Clean稳健
Leverage杠杆
Net debt / EBITDA净债务/EBITDA-4.43
Current ratio流动比率5.03
Capital allocation资本配置
Stock-based comp股权薪酬$38.8M
Share count change (1y)股数变化（1年）+2.0%
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚
Macro宏观
Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓
Insider cluster activity内部人集中交易
Technical技术面
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向： -$3.2M net (0 buyers, 6 sellers)-$3.2M 净值（0 买家，6 卖家）
Signal history信号历史
engine events引擎事件
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP. Buyers rejected the 2026-06-12 low (swing low printed) but price hasn't reclaimed its 10-day average — first box ticked, not all买入预备。买方拒绝了 2026-06-12 的低点（摆动低点已现），但价格尚未收复 10 日均线——第一项条件达成，并非全部
Jul 14, 2026
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP买入预备
Jul 14, 2026
VCEL daily MACD crossed downVCEL 日线MACD下穿
The daily MACD histogram turned negative — fast and noisy, context rather than a standalone trigger. $46.09.日线MACD柱状图转负 — 快速且嘈杂，仅作背景。$46.09。
Jul 7, 2026
VCEL made a new 52-week highVCEL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $46.95.价格创出52周新高 — 全市场关注的动量/趋势极值。$46.95。
Jul 2, 2026
VCEL made a new 52-week highVCEL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $46.98.价格创出52周新高 — 全市场关注的动量/趋势极值。$46.98。
Jun 25, 2026
VCEL made a new 52-week highVCEL 创52周新高
Price reached a fresh 52-week high — a momentum / trend extreme the whole market watches. $42.90.价格创出52周新高 — 全市场关注的动量/趋势极值。$42.90。
Jun 24, 2026
UPTREND → NEARING A HIGH上涨趋势 → 接近高点
TAKE PROFITS止盈
Jun 24, 2026
VCEL RSI reached overboughtVCEL RSI进入超买
RSI(14) crossed above 70 — stretched to the upside; context, not a timing trigger alone. $41.69.RSI(14)上穿70 — 上行过度；仅作背景，单独不构成择时。$41.69。
Jun 23, 2026
Golden cross on VCELVCEL 金叉
The 50-day average crossed above the 200-day — a slow, widely-watched bullish trend signal. $40.39.50日均线上穿200日均线 — 一个滞后但广受关注的看多趋势信号。$40.39。
Jun 23, 2026
NEARING A HIGH → UPTREND接近高点 → 上涨趋势
HOLD持有
Jun 22, 2026
UPTREND → NEARING A HIGH上涨趋势 → 接近高点
TAKE PROFITS止盈
Jun 22, 2026
VCEL RSI reached overboughtVCEL RSI进入超买
RSI(14) crossed above 70 — stretched to the upside; context, not a timing trigger alone. $40.47.RSI(14)上穿70 — 上行过度；仅作背景，单独不构成择时。$40.47。
Showing the last 15 of显示最近15条，共 259 signals条信号
Company profile公司档案
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.Vericel Corporation 是一家公开交易的美国生物制药公司，2014年10月前名为Aastrom Bio。Aastrom Bio于1989年在密歇根州安娜堡成立。
Style DNA — how it trades vs the market风格基因 — 相对市场的交易特征
Value价值
Below market低于市场
Profitability盈利能力
Above market高于市场
Quality质量
Below market低于市场
Investment资本投入
Below market低于市场
Low volatility低波动
Below market低于市场
Low market beta低市场敏感度
Below market低于市场
Earnings quality盈利质量
Below market低于市场
Short interest空头兴趣
Above market高于市场
Watch items — what could change the story关注项 — 可能改变故事的因素
- Receivables stretch
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Statistics — full detail统计数据 — 完整明细
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（静态） | 140.6× | 28.6× | 6% |
| Price / Book市净率 | 6.5× | 3.4× | 22% |
| Price / Sales市销率 | 8.4× | 3.0× | 14% |
| EV / EBITDAEV/EBITDA | 98.4× | 18.2× | 2% |
| Earnings yield盈利收益率 | 0.7% | 2.7% | 30% |
| Free-cash-flow yield自由现金流收益率 | 2.2% | 5.5% | 18% |
Relative strength相对强度
vs market, 1 month相对大盘（1个月）
33/100 — middle of the pack居中
vs market, 3 months相对大盘（3个月）
90/100 — stronger than most强于多数
vs market, 6 months相对大盘（6个月）
72/100 — stronger than most强于多数
vs market, 12 months相对大盘（12个月）
69/100 — middle of the pack居中
Rank in sector行业内排名
#109 / 165
0–100 percentile of total return vs all covered stocks.总回报在全部覆盖股票中的百分位（0–100）。
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | -3.4% | -0.9% |
| 1 Month近1月 | +14.4% | -0.6% |
| 3 Months近3月 | +36.3% | +5.4% |
| 6 Months近6月 | +21.6% | +8.6% |
| Year to date年初至今 | +28.8% | +8.9% |
| 1 Year近1年 | +29.8% | +19.2% |
| 3 Years近3年 | +18.5% | +69.9% |
Trading information交易信息
Beta vs market贝塔
1.06
Volatility rank波动率分位
35th pctile
Short interest空头占比
9.7% of float
Market cap市值
$2B
EPS (trailing)每股收益
$0.33
Off 52-week high距52周高点
-5.0%
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Financials — full detail财务数据 — 完整明细
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $124M | $156M | $164M | $198M | $237M | $276M |
| EPS每股收益 | $0.06 | $-0.16 | $-0.35 | $-0.07 | $0.20 | $0.32 |
| Free cash flow自由现金流 | $15M | $21M | $10M | $15M | $-6M | $25M |
| Gross margin毛利率 | 67.8% | 67.9% | 66.8% | 68.6% | 72.6% | 74.4% |
| Net margin净利率 | 2.3% | -4.8% | -10.2% | -1.6% | 4.4% | 6.0% |
| FCF margin自由现金流利润率 | 12.0% | 13.5% | 6.1% | 7.7% | -2.4% | 9.0% |
Latest fiscal year最近财年
Revenue (FY)营业收入（财年）
$276M
Gross profit毛利润
$206M
Net income净利润
$17M
Operating cash flow经营现金流
$52M
Total assets总资产
$488M
Shareholder equity股东权益
$355M
Shares outstanding总股本
0.05B
Returns & growth回报与增长
Return on equity股本回报率
4.7%
Return on assets资产回报率
3.4%
Profit growth利润增速
+59.4%
Asset growth资产增速
+12.8%
Accounting quality checks会计质量检查
- Earnings quality: accruals near the peer median盈利质量：应计利润接近同业中位
- Working capital: working capital roughly in line with sales营运资本：营运资本与销售大致同步
- Pricing power: gross margin +6.6pts over 6 years定价能力：毛利率 6 年上升 6.6 个百分点
- Capital discipline: share count +10.5% over 6 years (dilution)资本纪律：股本 6 年增加 10.5%（稀释）
- Balance sheet: Altman Z 10.5 — safe zone资产负债表：Altman Z 10.5——安全区
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Technicals — full detail技术面 — 完整明细
Indicator readings指标读数
RSI (14-day)RSI（14日）
58
RSI (2-day)RSI（2日）
21
vs 20-day average相对20日均线
+0.9%
vs 50-day average相对50日均线
+16.4%
vs 200-day average相对200日均线
+24.7%
Golden cross (50>200)金叉（50>200）
in effect生效中
MACDMACD
below signal位于信号线下方
Timeframe alignment多周期共振
Daily日线
momentum down动能向下
3-day3日线
momentum up动能向上
Weekly周线
momentum up动能向上
When daily through monthly point the same way, moves carry further.当日线到月线方向一致时，行情往往更有延续性。
Volatility regime波动状态
Range width percentile波幅宽度分位
70/100
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Earnings — full detail财务业绩 — 完整明细
Estimate revisions预期修正
Analysts covering覆盖分析师
1
Estimate direction预期调整方向
mostly raising多数上调
Estimate change, 90 days预期变化（90天）
+11.8%
Net upgrades, 30 days净上调（30天）
+1
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Ownership — full detail持仓 — 完整明细
Insiders & shorts内部人与空头
Insider net buying (6 months)内部人净买入（6个月）
-$3.2M
Insider buyers vs sellers内部人买家vs卖家
0 : 6
Short interest空头占流通盘
9.7%
Days to cover回补天数
5.3
Short interest change空头变化
-7.1%
Recent fund flows近期基金流向
SPDR S&P BiotechSPDR S&P Biotech
trimming减持
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Seasonality — full detail季节性 — 完整明细
Strongest month最强月份
Jan · 100%
Weakest month最弱月份
Feb · 33%
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 100% | +6.8% | 3 |
| Feb2月 | 33% | -0.2% | 3 |
| Mar3月 | 33% | -9.5% | 3 |
| Apr4月 | 33% | -12.1% | 3 |
| May5月 | 67% | +4.7% | 3 |
| Jun6月 | 75% | +11.2% | 4 |
| Jul7月 | 50% | +3.4% | 4 |
| Aug8月 | 67% | +3.0% | 3 |
| Sep9月 | 33% | -12.7% | 3 |
| Oct10月 | 100% | +6.2% | 3 |
| Nov11月 | 100% | +14.9% | 3 |
| Dec12月 | 33% | -5.5% | 3 |
History is a tendency, not a promise — small samples wobble.历史规律只是倾向而非保证 — 样本少时波动大。
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。